Lipidology Beyond Total Cholesterol: The Power of Ratios
For over four decades, clinical cardiology relied almost exclusively on Total Cholesterol ($TC$) as the primary screening biomarker for atherosclerotic cardiovascular disease ($ASCVD$). However, multiple clinical investigations, including the seminal Framingham Heart Study, revealed a profound paradox: more than 50% of individuals suffering acute myocardial infarctions possessed "normal" total cholesterol levels (< 200 mg/dL).
Total cholesterol reflects the sum total of sterol content across all circulating lipoproteins. However, different lipoprotein classes perform fundamentally opposing physiological functions:
- Atherogenic Particles (ApoB family): Low-Density Lipoproteins ($LDL$), Very-Low-Density Lipoproteins ($VLDL$), and Intermediate-Density Lipoproteins ($IDL$) carry cholesterol into arterial walls. When trapped in the subendothelial space of coronary arteries, they undergo oxidative modification, triggering macrophage phagocytosis, foam cell formation, and progressive atheromatous plaque accumulation.
- Anti-Atherogenic Particles (ApoA-I family): High-Density Lipoproteins ($HDL$) mediate reverse cholesterol transport, extracting excess cholesterol from peripheral arterial tissues and transporting it back to the liver for biliary excretion. Furthermore, HDL particles exert potent anti-inflammatory, anti-thrombotic, and antioxidant effects on the vascular endothelium.
Consequently, the ratio between atherogenic particles and protective HDL provides far superior prognostic power for predicting ischemic coronary events than total cholesterol alone.
Mathematical Definitions of the Core Lipid Ratios
1. Castelli Risk Index I (TC / HDL Ratio):
$$CRI\text{-}I = \frac{\text{Total Cholesterol}}{\text{HDL Cholesterol}}$$Formulated by Dr. William P. Castelli (former director of the Framingham Study), this ratio measures the overall balance between cholesterol entering tissues versus cholesterol being cleared.
- Optimal / Low Risk: < 3.5 in men; < 3.0 in women.
- Average Risk: 3.5 to 5.0.
- High Atherogenic Risk: > 5.0 (associated with a doubling of 10-year myocardial infarction risk).
2. Castelli Risk Index II (LDL / HDL Ratio):
$$CRI\text{-}II = \frac{\text{LDL Cholesterol}}{\text{HDL Cholesterol}}$$Focuses strictly on the direct ratio of primary atherogenic carriers to protective reverse transport carriers:
- Ideal Risk: < 2.0.
- Normal Risk: 2.0 to 3.2.
- Elevated Risk: > 3.5.
3. Triglyceride to HDL Ratio (TG / HDL) - The Insulin Resistance Marker:
$$\text{Ratio (mg/dL)} = \frac{\text{Triglycerides}}{\text{HDL}}\quad \Bigg|\quad \text{Ratio (mmol/L)} = \frac{\text{Triglycerides (mmol/L)}}{\text{HDL (mmol/L)}} \times 0.437$$The TG/HDL ratio is a validated surrogate biomarker for Atherogenic Dyslipidemia, hepatic insulin resistance, and the presence of small, dense LDL particles (sdLDL / Phenotype B). Small dense LDL particles are particularly dangerous because they easily penetrate damaged arterial endothelium, resist hepatic LDL-receptor binding, and are highly prone to oxidation.
- Ideal / High Insulin Sensitivity: < 1.5 (< 0.65 in mmol/L).
- Normal: 1.5 to 2.5 (0.65 to 1.10 in mmol/L).
- High / Insulin Resistance & Small Dense LDL: > 3.0 (> 1.30 in mmol/L).
4. Non-HDL Cholesterol:
$$\text{Non-HDL} = \text{Total Cholesterol} - \text{HDL Cholesterol}$$Non-HDL encapsulates the full atherogenic burden ($LDL + VLDL + IDL + Lp(a)$). The American Heart Association (AHA) and National Lipid Association (NLA) designate Non-HDL as a secondary target of therapy:
- Optimal: < 100 mg/dL (< 2.6 mmol/L).
- Desirable: < 130 mg/dL (< 3.4 mmol/L).
- High Risk: ≥ 160 mg/dL (≥ 4.1 mmol/L).
Comprehensive Cardiovascular Risk Stratification Table
The table below demonstrates risk categories across all primary ratios in both US standard (mg/dL) and International System (mmol/L) units:
| Risk Category | Castelli I (TC/HDL) | Castelli II (LDL/HDL) | TG / HDL Ratio (mg/dL) | Non-HDL (mg/dL) | Non-HDL (mmol/L) | Clinical Interpretation |
|---|---|---|---|---|---|---|
| Optimal / Low Risk | < 3.5 (Men) < 3.0 (Women) |
< 2.0 | < 1.5 | < 100 | < 2.6 | Minimal atherogenic plaque progression; high insulin sensitivity; large buoyant LDL. |
| Moderate / Desirable | 3.5: 4.5 | 2.0: 3.0 | 1.5: 2.5 | 100: 129 | 2.6: 3.3 | Average population risk; balanced reverse cholesterol transport. |
| Borderline High | 4.6: 5.0 | 3.1: 3.5 | 2.6: 3.2 | 130: 159 | 3.4: 4.1 | Early endothelial dysfunction; lifestyle intervention (dietary fiber, aerobic training) indicated. |
| High Risk | 5.1: 6.0 | 3.6: 4.5 | 3.3: 4.0 | 160: 189 | 4.1: 4.9 | Substantial excess cardiovascular risk; small dense LDL phenotype; consider statin therapy. |
| Very High Risk | > 6.0 | > 4.5 | > 4.0 | ≥ 190 | ≥ 4.9 | Accelerated coronary atherogenesis; metabolic syndrome; aggressive lipid-lowering required. |
Worked Clinical Cardiology Case Study
Unmasking Hidden Atherogenic Risk in "Normal" Cholesterol
Advanced Lipidology: Apolipoprotein B and Particle Discordance
While standard lipid panels report the mass of cholesterol carried within lipoproteins (e.g., mg of LDL cholesterol per deciliter of plasma), atherosclerotic plaque initiation is governed by the absolute number of circulating atherogenic particles. Each atherogenic particle, whether an LDL, VLDL, IDL, or Lipoprotein(a), carries exactly one molecule of Apolipoprotein B (ApoB-100) on its outer phospholipid shell.
In patients with metabolic syndrome, visceral obesity, or type 2 diabetes, a dangerous clinical phenomenon termed LDL Particle Discordance frequently occurs:
- Concordant Profile: Normal LDL-C accompanied by normal ApoB particle number (low cardiovascular risk).
- Discordant High-Risk Profile: "Normal" LDL-C (e.g., 95 mg/dL) paired with a severely elevated ApoB particle count (> 110 mg/dL). This occurs because high circulating triglycerides stimulate cholesterol ester transfer protein (CETP) to exchange triglycerides into LDL in return for cholesterol esters. Hepatic lipase then hydrolyzes these triglyceride-enriched particles, creating millions of small, cholesterol-depleted, dense LDL particles. Even though each particle carries less total cholesterol mass, the total particle count is massive, and cardiovascular risk tracks strictly with particle number (ApoB), not cholesterol mass.
When advanced NMR lipoprofile or ApoB immunoassay testing is unavailable, the combination of an elevated Castelli Risk Index I (> 4.5) and a high TG/HDL ratio (> 3.0) serves as a virtually cost-free, highly sensitive clinical surrogate identifying patients with discordant, highly atherogenic small dense LDL profiles requiring aggressive lifestyle and pharmacologic intervention.